key: cord-1050672-hp3yrpe5
authors: Rabin-Havt, Sara; Blanco-Breindel, Miranda; Suskin, Emily; Bina, Michelle; Dar, Pe’er; Klugman, Susan
title: eP499 Prenatal genetic screening and diagnostic testing during the COVID-19 pandemic in the Bronx, NY
date: 2021-04-30
journal: Molecular Genetics and Metabolism
DOI: 10.1016/s1096-7192(21)00577-1
sha: 3ba97650bd1e66c35dd4edd4d27cddff9286ab17
doc_id: 1050672
cord_uid: hp3yrpe5

Introduction: The Coronavirus Disease (COVID-19) pandemic has changed the landscape of both inpatient and outpatient healthcare. During the height of the pandemic, most elective and many nonelective procedures were halted. Prenatal care services including ultrasound and genetic screening and testing remained active (given gestational age dependence) while shifting from in-person towards telehealth counseling. NewYork Citywas at the epicenter of the pandemic fromMarch through June 2020. Elective procedures at Montefiore Medical Center, which serves a diverse urban population in the Bronx, NY,were cancelled from March 16, 2020 to June 20, 2020. Prenatal ultrasound shifted from a dating ultrasound and a nuchal translucency ultrasound to one first trimester ultrasound and anatomy scans were scheduled at 20–22 weeks gestation rather than 18–20 weeks. The majority of counseling sessions were conducted via telehealth and prenatal diagnostic procedures (including amniocentesis and chorionic villus sampling [CVS]) were performed with a limited team to adhere to COVID-19 protocols. We examined the impact of this shift on rates of prenatal genetic screening and diagnostic procedures before and during the COVID-19 pandemic. Previous literature has revealed that since the advent of noninvasive prenatal screening (NIPS), prenatal genetic diagnostic procedures rates have been on the decline.We hypothesized that the rate of genetic diagnostic procedure rates would decrease and NIPS would increase as compared to the similar period in 2019. Methods: Retrospective analysis of data collected in a secure institutional logbook at Montefiore Medical Center Department of Obstetrics & Gynecology and Women’s Health (Division of Reproductive and Medical Genetics and Division of Fetal Medicine and Ultrasound) from January 1, 2019–December 31, 2020. Collected data included number of procedures, gestational age, and indication for procedure (categorized as advanced maternal age (AMA), ultrasound anomalies, positive screening test, hereditary disease in the family possibly affecting fetus (including family history or genetic carrier), or other. Procedures for multiple gestations were considered as a single procedure.. Results: 503 diagnostic procedures (359 amniocenteses and 144 CVS) were included. Most common indication (ultrasound anomaly) and average gestational age (13 weeks for CVS and 19 weeks for amniocentesis) were the same in 2019 and 2020. In total, 275 procedures were performed in 2019 as compared to 228 in 2020 (20.6% decrease) ( p = 0.018). Specifically, amniocentesis decreased from 187 to 172 (8% decrease) ( p = 0.214) and CVS decreased from 88 to 56 (36% decrease) ( p = 0.004). NIPS increased from 1,312 tests in 2019 to 1727 tests in 2020 (31.6%) ( p < 0.001). The same data points were then analyzed during the four-month period at the height of the pandemic in New York City. We compared numbers of procedures from the period March 1, 2019–June 30, 2019 to March 1, 2020–June 30, 2020. Total prenatal diagnostic procedures during this period were 91 in 2019 and 81 in 2020 (12.3% decrease). This included 59 amniocenteses compared with 60 in the same period in 2020 (1.6% increase) and 32 CVS in 2019 compared to 21 in 2020 (34.3% decrease). Noninvasive prenatal screening increased from 348 to 510 (increase of 46.5%) during this period. Discussion: At Montefiore Medical Center in the Bronx, NY, prenatal genetic diagnostic procedures decreased while NIPS rates increased during the pandemic. This trend may reflect patient’s concerns for a COVID-19 exposure during in-office procedures, shift to telehealth counseling, or be reflective of the overall trends seen since the widespread offering of NIPS to prenatal patients. The decrease in CVS may be explained by an intentional system delay of combining ultrasound and blood draw to a single visit at the end of the first trimester. Future studies should investigate how access to care and gestational age at the time of presentation influenced prenatal genetic screening and testing cho ces during the pandemic, in order to better explain the identified trends.

Results: Previous publications attribute 8.9% of CHD cases to a subset of aneuploidies (trisomies 21, 18 and 13, and monosomy X) and 1.9% to 22q11.2 microdeletions (Table 1) . Using the most conservative test platform sensitivities reported, chromosomal NIPT was estimated to identify 9.8% of all CHD cases. The conditions identified using singlegene NIPT were associated with 3.3% of CHD cases (Table 2) . With the most conservative sensitivities, single-gene NIPT was estimated to identify 2.3% of CHD cases. Thus, NIPT for aneuploidy and single-gene alterations combined determined the cause of at least 12.2% of CHD cases in the meta-analysis.

Conclusions: The majority of CHD cases are believed to be multifactorial and unattributable to a genetic or environmental cause. Screening for the common aneuploidies, the 22q11.2 deletion and select single gene disorders through chromosomal and singlegene NIPT identifies the cause of between 40-60% of CHD cases with a genetic etiology. For some couples who wish to avoid or enhance invasive diagnostic testing, these screening options may be useful in determining the underlying cause for CHD in the pregnancy. A prenatal genetic diagnosis or suspected diagnosis can help providers give appropriate medical referrals including genetic counseling and can help couples make decisions about additional testing and pregnancy management decisions. During the height of the pandemic, most elective and many nonelective procedures were halted. Prenatal care services including ultrasound and genetic screening and testing remained active (given gestational age dependence) while shifting from in-person towards telehealth counseling. New York City was at the epicenter of the pandemic from March through June 2020. Elective procedures at Montefiore Medical Center, which serves a diverse urban population in the Bronx, NY, were cancelled from March 16, 2020 to June 20, 2020. Prenatal ultrasound shifted from a dating ultrasound and a nuchal translucency ultrasound to one first trimester ultrasound and anatomy scans were scheduled at 20-22 weeks gestation rather than 18-20 weeks. The majority of counseling sessions were conducted via telehealth and prenatal diagnostic procedures (including amniocentesis and chorionic villus sampling [CVS]) were performed with a limited team to adhere to COVID-19 protocols. We examined the impact of this shift on rates of prenatal genetic screening and diagnostic procedures before and during the COVID-19 pandemic. Previous literature has revealed that since the advent of noninvasive prenatal screening (NIPS), prenatal genetic diagnostic procedures rates have been on the decline. We hypothesized that the rate of genetic diagnostic procedure rates would decrease and NIPS would increase as compared to the similar period in 2019. Methods: Retrospective analysis of data collected in a secure institutional logbook at Montefiore Medical Center Department of Obstetrics & Gynecology and Women's Health (Division of Reproductive and Medical Genetics and Division of Fetal Medicine and Ultrasound) from January 1, 2019-December 31, 2020. Collected data included number of procedures, gestational age, and indication for procedure (categorized as advanced maternal age (AMA), ultrasound anomalies, positive screening test, hereditary disease in the family possibly affecting fetus (including family history or genetic carrier), or other. Procedures for multiple gestations were considered as a single procedure.. Results: 503 diagnostic procedures (359 amniocenteses and 144 CVS) were included. Most common indication (ultrasound anomaly) and average gestational age (13 weeks for CVS and 19 weeks for amniocentesis) were the same in 2019 and 2020. In total, 275 procedures were performed in 2019 as compared to 228 in 2020 (20.6% decrease) ( p = 0.018). Specifically, amniocentesis decreased from 187 to 172 (8% decrease) ( p = 0.214) and CVS decreased from 88 to 56 (36% decrease) ( p = 0.004). NIPS increased from 1,312 tests in 2019 to 1727 tests in 2020 (31.6%) ( p < 0.001). The same data points were then analyzed during the four-month period at the height of the pandemic in New York City. We compared numbers of procedures from the period March 1, 2019-June 30, 2019 to March 1, 2020-June 30, 2020. Total prenatal diagnostic procedures during this period were 91 in 2019 and 81 in 2020 (12.3% decrease). This included 59 amniocenteses compared with 60 in the same period in 2020 (1.6% increase) and 32 CVS in 2019 compared to 21 in 2020 (34.3% decrease). Noninvasive prenatal screening increased from 348 to 510 (increase of 46.5%) during this period. Discussion: At Montefiore Medical Center in the Bronx, NY, prenatal genetic diagnostic procedures decreased while NIPS rates increased during the pandemic. This trend may reflect patient's concerns for a COVID-19 exposure during in-office procedures, shift to telehealth counseling, or be reflective of the overall trends seen since the widespread offering of NIPS to prenatal patients. The decrease in CVS may be explained by an intentional system delay of combining ultrasound and blood draw to a single visit at the end of the first trimester. Future studies should investigate how access to care and gestational age at the time of presentation influenced prenatal genetic screening and testing choices during the pandemic, in order to better explain the identified trends. Carrier screen panels for preconceptional and pregnant women frequently include X-linked (XL) disorders. The selection of the XL conditions that are included on such panels, commonly referred to as expanded carrier screening, vary widely across different commercial laboratories. Aworkgroup was convened by ACMG to update a position statement on expanded carrier screening. A subgroup from this team investigated the XL conditions that would qualify for inclusion on a carrier screen panel. Methods: A list of XL genes associated with known phenotypes was obtained from OMIM, (omim.org, accessed Nov 30, 2020). Each identified gene was reviewed for associated disease phenotypes. Only XL recessive conditions were considered for carrier screen panels, as they generally have no or only mild phenotypic consequences prior to the reproductive years of female carriers. Information on carrier phenotypes was researched using OMIM, GeneReviews, PubMed, and other published resources. Mild or easily treatable conditions were removed from further consideration by consensus. We decided that a carrier prevalence of at least 1/40,000 females was required in order for the XL disorder to be included. This is based in part on approximating a disease prevalence of autosomal recessive conditions with a carrier frequency of 1/200. However, because prevalence of XL conditions is frequently uncertain, we used a variety of databases to ascertain or deduce the carrier frequency. If disease prevalence was estimated within reasonable proximity to carrier frequency of 1/ 40,000 females, then that disorder was included. Results: There were 354 unique XL phenotypes catalogued by OMIM. In several instances, a single XL gene was associated with multiple unique phenotypes. After removing the duplicates, a list of 237 XL genes was selected for further curation. We identified 18 XL genes that were deemed suitable for inclusion on carrier panels. Some XL genes included are not currently available on carrier screening panels because of analytic testing challenges due to the nature of gene variants associated with the common phenotype (e.g., inversion in F8 gene associated with Factor VIII deficiency). The possibility of skewed X inactivation is recognized and could result in abnormal phenotype, but this possibility applies to virtually all XL genes. Specific features of relevant XL genes that frequently manifest in carrier females are delineated. Conclusion: Inclusion of XL conditions in carrier screen panels requires a clear justification based on the sex-based differences in carrier frequency and phenotype. We identified a paucity of data available on these characteristics for XL conditions and, thus, recommend further investigation with a focus on these conditions. Counseling patients pre-and post-test regarding variants in XL genes poses added challenges for the clinician. Several XL genes may manifest some phenotypic consequences in female carriers, albeit milder, later in life, or of a different nature than in hemizygous males. Thus, additional information should be relayed to the woman when considering carrier screening panels that include XL conditions. 

While NIPT screening is the standard of care for initial prenatal testing, positive NIPT tests, high risk pregnancies or abnormal ultrasounds are typically followed by invasive testing. This most often involves collection of amniotic fluid to establish amniocyte cultures that are then used for Karyotyping, FISH and CMA. The Bionano Saphry platform is being evaluated for use in laboratory developed tests (LDTs) aimed at replacing all three of the legacy tests using amniocyte cultures. For our prenatal workflow, five independent amniocyte cultures in T75 flasks filled with DMEM were evaluated. After a 6 hour equilibration in the 37°C, 5% CO 2 incubator, the DMEM was removed and 12 ml of growth medium (AmnioMax II Complete Medium) was added. When the cultures reached approximately 80-90% confluency, the growth medium was removed and the cultures were briefly rinsed with phosphate buffered saline (PBS, pH 7.4). After adding 3 ml of trypsin/ EDTA, the flasks which were returned to the incubator for 2-3 min. The cells were dislodged by gentle pipetting of the tryspin/EDTA across the surface and 10 ml PBS was added to dilute the trypsin and to dislodge any remaining adherent cells from the substratum. Cell suspensions were transferred to 15 ml conical tubes and cells pelleted by centrifugation for 2 minutes at 2000 × g. The cells were then resuspended in 2 ml of DNA stabilization buffer (DSB) and counted in a hemocytometer (trypan blue). While targeting ∼ 1 million cells per culture for this study, the cultures yielded between 0.52 and 0.9 million cells. The cells were pelleted for 2 min at 2,000 × g and the supernatants removed. The cell pellets were processed using the Bionano Prep SP Fresh Cells DNA Isolation Protocol to isolate ultra-high molecular weight genomic DNA. The isolated genomic DNA concentrations were all above the

2 Deletion Syndrome

Alpert Syndrome

Cornelia de Lange Syndrome

GeneReviews. Updated Aug